4.21 USD
↗ 0.02 (0.48%)AT CLOSE (AS OF 07:26 PM EDT)
Prelude Therapeutics Incorporated
PRLDNASDAQ • USD
Market: CLOSED
Prelude Therapeutics Incorporated (PRLD) trades at $4.21 per share. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, PRLD is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jul 17, 2026.
Open?$4.08
High?$4.31
Low?$4.01
Prev. Close?$4.18
Volume?180.7K
Avg. Volume?487.8K
VWAP?$4.22
Rel. Volume?0.37x
Bid / Ask
Bid?$3.62 × 100
Ask?$4.78 × 100
Spread?$1.16
Midpoint?$4.20
Valuation & Ratios
Market Cap?332.9M
Shares Out?79.6M
Float?17.1M
Float %?39.0%
P/E Ratio?N/A
P/B Ratio?5.53
EPS?-$0.98
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Themes
Employees
79
Market Cap
332.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-09-25
Address
175 INNOVATION BOULEVARD
WILMINGTON, DE 19805
Phone: (302) 467-1280
WILMINGTON, DE 19805
Phone: (302) 467-1280
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?73
Short Sent.?21
Piotroski F-Score?0/9Weak
Altman Z-Score?-6.51Distress
Confidence?47%Low
Short InterestHigh
Short % of Float?16.55%High
Short Interest?2.8M
Days to Cover?3.5
Free Float17.1M
Avg Daily Volume812.1K
Settlement Date2026-06-30
Financial Health
Current Ratio?2.03Strong
Quick Ratio?2.03Strong
Cash Ratio?0.52Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?5.53FAIR▾
Peers100
S&P34
P/S?19.91HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-3.8CHEAP▾
S&P97
EV/Sales?18.61HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-129.3%WEAK▾
S&P3
ROA?-65.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-43776000
Enterprise Value?$311.2M
Fundamentals ratios updated end of day